Kiniksa Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Kiniksa Pharmaceuticals's estimated annual revenue is currently $19.8M per year.
- Kiniksa Pharmaceuticals's estimated revenue per employee is $88,000
- Kiniksa Pharmaceuticals's total funding is $400M.
- Kiniksa Pharmaceuticals's current valuation is $780.5M. (January 2022)
- Kiniksa Pharmaceuticals has 225 Employees.
- Kiniksa Pharmaceuticals grew their employee count by 13% last year.
Kiniksa Pharmaceuticals Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Kiniksa Pharmaceuticals?
Kiniksa is a publicly traded biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have a pipeline of product candidates across various stages of development focused on autoinflammatory and autoimmune conditions that have the potential to address multiple indications. We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines. We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company. Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.keywords:N/A
Number of Employees
Employee Growth %
Kiniksa Pharmaceuticals News
Bank of America dropped their price target on Kiniksa Pharmaceuticals from $37.00 to $34.00 and set a buy rating on the stock in a research...
Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Will Announce Earnings of -$0.40 Per Share. Posted by admin on Apr 12th,...
Comparatively, Kiniksa Pharmaceuticals has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Insider and...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|